It is no longer the current profile. Read the canonical profile and its correction notice.
What this version reported
FDA states that it lacks sufficient safety information on LL-37 in people and cites nonclinical findings of harm to male reproduction and tumor promotion. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗
Reader guide in this version
Key takeaway
LL-37 is a 37-amino-acid peptide of the human cathelicidin family, recorded in FDA’s substance registry as cathelicidin LL-37 (human), with the international name ropocamptide.1 FDA lists cathelicidin LL-37 among compounding substances that may present significant safety risks. It states that it lacks enough safety information to know whether LL-37 would cause harm in people.2 FDA also notes nonclinical findings suggesting harm to male reproduction and that LL-37 can promote tumors in some tissues. No FDA approval is reported in the sources reviewed here, and LL-37 is not among the six peptides in HHS’s October 2026 draft policy.2,4
At a glance
- What it is
- A 37-amino-acid peptide beginning with two leucines (hence LL-37), recorded as human cathelicidin LL-37 and ropocamptide in FDA’s substance registry.1
- FDA status
- No FDA approval is reported in the sources reviewed here. FDA lists cathelicidin LL-37 among bulk substances whose compounding nominations were withdrawn and that may present significant safety risks.2
- Human evidence
- FDA states that it lacks sufficient safety information for LL-37 in people. The FDA sources reviewed here describe only nonclinical research findings.2
- Evidence strength
- Animal and lab studies only
What is LL-37?
LL-37 is a peptide of 37 amino acids, starting with two leucines, that FDA’s substance registry records as cathelicidin LL-37 (human) and under the international nonproprietary name ropocamptide.1
How is LL-37 thought to work?
The FDA sources reviewed here do not describe how LL-37 works. They report nonclinical findings on its possible harms rather than its intended effects.1,2
What do human studies show?
FDA states that it lacks sufficient safety-related information on cathelicidin LL-37 to know whether it would cause harm when given to humans.2
The FDA sources reviewed here do not describe human trials of LL-37 or evaluate whether it is effective for any use.2
What the evidence base contains
- Animal or laboratory research Nonclinical research findings, cited by FDA, suggesting harmful effects on male reproduction and that LL-37 can promote tumor growth in some tissues.2
Evidence-strength label: Animal and lab studies only. How this label is assigned
Is LL-37 FDA-approved?
None of the sources reviewed here reports an approval of LL-37 by FDA.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, lists cathelicidin LL-37 among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions and characterization problems.2
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. LL-37 is not among them.3,4
Timeline
- FDA’s compounding safety-risk page, as last updated, lists cathelicidin LL-37 among withdrawn nominations with safety concerns.2
What is still unknown?
Whether it is safe in people, which FDA states it lacks the information to judge.2
Whether the reproductive and tumor-promoting effects seen in nonclinical research apply to people.2
Sources for this version
- 1Ropocamptide (cathelicidin LL-37, human) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 2Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 4HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026